Journey Medical Corporation (DERM)
USD 6.96
(9.95%)
USD 6.96
(9.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.92 Million USD | 117.94% |
| 2022 | -23.18 Million USD | -8.36% |
| 2021 | -32.76 Million USD | -370.51% |
| 2020 | 9.36 Million USD | 43.6% |
| 2019 | 6.43 Million USD | 103.17% |
| 2018 | -205.54 Million USD | 30.27% |
| 2017 | -294.78 Million USD | -237.2% |
| 2016 | -87.42 Million USD | -10.94% |
| 2015 | -78.8 Million USD | -149.03% |
| 2014 | -31.64 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.08 Million USD | 78.37% |
| 2024 Q1 | -9.25 Million USD | -684.24% |
| 2023 FY | - USD | 117.94% |
| 2023 Q3 | 17.25 Million USD | 489.37% |
| 2023 Q4 | -1.26 Million USD | -107.34% |
| 2023 Q1 | -8.34 Million USD | 16.06% |
| 2023 Q2 | -4.43 Million USD | 46.92% |
| 2022 Q2 | -6.09 Million USD | -4827.91% |
| 2022 FY | - USD | -8.36% |
| 2022 Q1 | 129 Thousand USD | 101.42% |
| 2022 Q4 | -9.94 Million USD | -17.69% |
| 2022 Q3 | -8.45 Million USD | -38.55% |
| 2021 Q2 | -13 Million USD | -1192.52% |
| 2021 Q3 | -3.1 Million USD | 76.11% |
| 2021 Q4 | -9.05 Million USD | -191.6% |
| 2021 FY | - USD | -370.51% |
| 2021 Q1 | 1.19 Million USD | -70.29% |
| 2020 Q3 | 618 Thousand USD | -59.84% |
| 2020 FY | - USD | 43.6% |
| 2020 Q2 | 1.53 Million USD | -34.5% |
| 2020 Q4 | 4 Million USD | 548.06% |
| 2020 Q1 | 2.34 Million USD | 0.0% |
| 2019 Q1 | -61.02 Million USD | 10.82% |
| 2019 FY | - USD | 103.17% |
| 2019 Q3 | -53.08 Million USD | -274.13% |
| 2019 Q2 | -14.18 Million USD | 76.75% |
| 2018 Q2 | -16.56 Million USD | 68.89% |
| 2018 Q3 | -62.72 Million USD | -278.57% |
| 2018 Q4 | -68.42 Million USD | -9.08% |
| 2018 FY | - USD | 30.27% |
| 2018 Q1 | -53.26 Million USD | -1.4% |
| 2017 Q1 | -29.42 Million USD | -300.49% |
| 2017 FY | - USD | -237.2% |
| 2017 Q4 | -52.52 Million USD | 70.07% |
| 2017 Q3 | -175.51 Million USD | -375.25% |
| 2017 Q2 | -36.93 Million USD | -25.5% |
| 2016 Q4 | -7.34 Million USD | 70.24% |
| 2016 Q3 | -24.68 Million USD | 56.33% |
| 2016 FY | - USD | -10.94% |
| 2016 Q2 | -56.53 Million USD | -96.13% |
| 2016 Q1 | -28.82 Million USD | 63.73% |
| 2015 Q1 | -14.43 Million USD | -111.32% |
| 2015 Q2 | -31.66 Million USD | -119.39% |
| 2015 Q3 | -16.53 Million USD | 47.79% |
| 2015 FY | - USD | -149.03% |
| 2015 Q4 | -79.46 Million USD | -380.73% |
| 2014 Q4 | -6.83 Million USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alvotech | -484.86 Million USD | 100.396% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 99.377% |
| Dynavax Technologies Corporation | 9.66 Million USD | 80.126% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 101.209% |
| PainReform Ltd. | -9.56 Million USD | 120.075% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 150.23% |
| SCYNEXIS, Inc. | 73.47 Million USD | 97.386% |
| Silver Spike Investment Corp. | 7.34 Million USD | 73.829% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | 150.23% |
| Bright Green Corporation | - USD | -Infinity% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 101.28% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | -62.521% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 98.243% |
| Alpha Teknova, Inc. | -25.53 Million USD | 107.522% |
| Embecta Corp. | 245.4 Million USD | 99.217% |
| Safety Shot Inc | -12.18 Million USD | 115.765% |
| Procaps Group, S.A. | 104.02 Million USD | 98.153% |
| Cosmos Health Inc. | -17.06 Million USD | 111.259% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | 181.71% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 98.821% |
| Theratechnologies Inc. | -10.31 Million USD | 118.627% |
| Harrow Health, Inc. | 9.72 Million USD | 80.243% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | 142.453% |
| Biofrontera Inc. | -18.45 Million USD | 110.41% |
| DURECT Corporation | -24.68 Million USD | 107.782% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 98.045% |
| Cronos Group Inc. | -72.14 Million USD | 102.663% |
| OptiNose, Inc. | -15.55 Million USD | 112.351% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 100.208% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 105.324% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 92.686% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 94.668% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | 148.976% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | 370.24% |
| Radius Health, Inc. | 38.31 Million USD | 94.986% |
| Universe Pharmaceuticals INC | -3.21 Million USD | 159.75% |
| ProPhase Labs, Inc. | -14.82 Million USD | 112.956% |
| Phibro Animal Health Corporation | 84.6 Million USD | 97.73% |
| Procaps Group S.A. | 104.02 Million USD | 98.153% |
| TherapeuticsMD, Inc. | -8.4 Million USD | 122.866% |
| Viatris Inc. | 3.51 Billion USD | 99.945% |
| Rockwell Medical, Inc. | -4.69 Million USD | 140.925% |
| Aytu BioPharma, Inc. | -1.01 Million USD | 289.822% |
| SIGA Technologies, Inc. | 84.15 Million USD | 97.717% |
| Tilray Brands, Inc. | -72.84 Million USD | 102.637% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | -136.576% |
| Shineco, Inc. | -26.55 Million USD | 107.234% |
| PetIQ, Inc. | 81.48 Million USD | 97.643% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | 153.101% |
| Incannex Healthcare Limited | -18.5 Million USD | 110.382% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 99.538% |
| Alimera Sciences, Inc. | 7.27 Million USD | 73.598% |
| Assertio Holdings, Inc. | -222.44 Million USD | 100.864% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | 148.138% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | 145.609% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | 111.432% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 109.59% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 101.288% |
| Hempacco Co., Inc. | -12.77 Million USD | 115.039% |
| Talphera, Inc. | -9.84 Million USD | 119.518% |
| Alvotech | -484.86 Million USD | 100.396% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 97.521% |
| Lantheus Holdings, Inc. | 491 Million USD | 99.609% |
| Currenc Group, Inc. | -1.9 Million USD | 201.075% |
| Kamada Ltd. | 21.53 Million USD | 91.079% |
| Indivior PLC | 66 Million USD | 97.089% |
| Evoke Pharma, Inc. | -7.29 Million USD | 126.343% |
| Flora Growth Corp. | -45.87 Million USD | 104.188% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 109.59% |
| Evolus, Inc. | -41.81 Million USD | 104.595% |
| HUTCHMED (China) Limited | 25.52 Million USD | 92.475% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 99.204% |
| Akanda Corp. | -27.73 Million USD | 106.926% |